Novartis AG
NVS119.450USD
-1.280-1.06%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
234.03BMarket Cap
19.60P/E TTM
More Details of Novartis AG Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
Ticker SymbolNVS
Company nameNovartis AG
IPO dateMay 07, 2001
Founded at1996
CEODr. Vasant (Vas) Narasimhan, M.D.
Number of employees75883
Security typeOrdinary Share
Fiscal year-endMay 07
AddressLichtstrasse 35
CityBASEL
Stock exchangeJohannesburg Stock Exchange
CountrySwitzerland
Postal code4056
Phone41613241111
Websitehttps://www.novartis.com/
Ticker SymbolNVS
IPO dateMay 07, 2001
Founded at1996
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Dr. Steffen Lang, Ph.D.
Dr. Steffen Lang, Ph.D.
President - Operations, Member of the Executive Committee
President - Operations, Member of the Executive Committee
--
--
Mr. Harry Kirsch
Mr. Harry Kirsch
Chief Financial Officer, Member of the Executive Committee
Chief Financial Officer, Member of the Executive Committee
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
By RegionUSD
Name
Revenue
Proportion
United States
21.15B
42.03%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
0.60%
PRIMECAP Management Company
0.53%
Dimensional Fund Advisors, L.P.
0.44%
Fisher Investments
0.35%
Loomis, Sayles & Company, L.P.
0.28%
Other
97.80%
Shareholders
Shareholders
Proportion
Dodge & Cox
0.60%
PRIMECAP Management Company
0.53%
Dimensional Fund Advisors, L.P.
0.44%
Fisher Investments
0.35%
Loomis, Sayles & Company, L.P.
0.28%
Other
97.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.16%
Investment Advisor/Hedge Fund
3.00%
Research Firm
0.50%
Hedge Fund
0.33%
Bank and Trust
0.11%
Pension Fund
0.03%
Family Office
0.01%
Other
92.84%
Institutional Shareholding
Updated: Thu, Feb 20
Updated: Thu, Feb 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1921
132.66M
6.77%
-8.92M
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
2023Q1
1762
167.49M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
12.21M
0.62%
-7.21K
-0.06%
Dec 31, 2024
PRIMECAP Management Company
11.03M
0.56%
-983.02K
-8.19%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Fisher Investments
2.00M
0.1%
+296.95K
+17.41%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.58M
0.28%
-192.68K
-3.34%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.22%
-16.98K
-0.40%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.98M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Wellington Management Company, LLP
3.65M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Managed Account Advisors LLC
2.95M
0.15%
-214.17K
-6.76%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
VanEck Pharmaceutical ETF
4.58%
Amplify International Enhanced Dividend Income ETF
3.56%
Altrius Global Dividend ETF
2.74%
Abacus FCF International Leaders ETF
2.7%
Invesco International Dividend Achievers ETF
2.28%
Pacer Global Cash Cows Dividend ETF
2.24%
Freedom Day Dividend ETF
2.08%
SP Funds S&P World (ex-US) ETF
1.8%
Brandes International ETF
1.65%
SGI Enhanced Global Income ETF
1.52%
View more
VanEck Pharmaceutical ETF
Proportion4.58%
Amplify International Enhanced Dividend Income ETF
Proportion3.56%
Altrius Global Dividend ETF
Proportion2.74%
Abacus FCF International Leaders ETF
Proportion2.7%
Invesco International Dividend Achievers ETF
Proportion2.28%
Pacer Global Cash Cows Dividend ETF
Proportion2.24%
Freedom Day Dividend ETF
Proportion2.08%
SP Funds S&P World (ex-US) ETF
Proportion1.8%
Brandes International ETF
Proportion1.65%
SGI Enhanced Global Income ETF
Proportion1.52%
Dividend
A total of
36.74B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 20, 2025
NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025
Mar 12, 2025
May 01, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
